TNDM has been the topic of several other reports. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a hold rating to a buy rating and set a $2.75 price objective on the stock in a research note on Saturday, January 6th. ValuEngine lowered shares of Tandem Diabetes Care from a sell rating to a strong sell rating in a research note on Thursday, March 1st. Citigroup initiated coverage on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th. They set an outperform rating and a $5.50 price objective on the stock. Cowen restated a hold rating on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th. Finally, Stifel Nicolaus restated a hold rating and set a $4.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, March 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. Tandem Diabetes Care currently has an average rating of Hold and an average price target of $9.42.
Shares of Tandem Diabetes Care stock opened at $3.99 on Thursday. The company has a debt-to-equity ratio of -2.63, a current ratio of 1.78 and a quick ratio of 1.03. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $13.00.
In other news, Director Christopher J. Twomey acquired 75,000 shares of the stock in a transaction dated Friday, February 9th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dick Allen acquired 25,539 shares of the stock in a transaction dated Tuesday, March 6th. The shares were purchased at an average price of $3.88 per share, for a total transaction of $99,091.32. The disclosure for this purchase can be found here. Insiders have bought a total of 850,539 shares of company stock worth $1,749,091 over the last 90 days. 20.90% of the stock is owned by company insiders.
A hedge fund recently raised its stake in Tandem Diabetes Care stock. Vanguard Group Inc. boosted its stake in Tandem Diabetes Care Inc (NASDAQ:TNDM) by 2.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,233,607 shares of the medical device company’s stock after buying an additional 32,991 shares during the period. Vanguard Group Inc. owned approximately 2.46% of Tandem Diabetes Care worth $987,000 as of its most recent filing with the SEC. 8.74% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3298890/tandem-diabetes-care-tndm-rating-reiterated-by-oppenheimer.html.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.